Skip to main content

The biological function of the cellular prion protein: an update


The misfolding of the cellular prion protein (PrPC) causes fatal neurodegenerative diseases. Yet PrPC is highly conserved in mammals, suggesting that it exerts beneficial functions preventing its evolutionary elimination. Ablation of PrPC in mice results in well-defined structural and functional alterations in the peripheral nervous system. Many additional phenotypes were ascribed to the lack of PrPC, but some of these were found to arise from genetic artifacts of the underlying mouse models. Here, we revisit the proposed physiological roles of PrPC in the central and peripheral nervous systems and highlight the need for their critical reassessment using new, rigorously controlled animal models.

The cellular prion protein (PrPC) is a cell surface protein expressed in a variety of different organs and tissues with high expression levels in the central and peripheral nervous systems [1]. It is mainly known for its infamous role in prion diseases, where its misfolding and aggregation cause inevitably fatal neurodegenerative conditions [2]. Prion diseases are transmissible and misfolded prion protein (PrPSc) is—according to the “protein-only hypothesis’”—the only disease-causing agent [3]. Under this view, it is puzzling that a protein underlying such severe diseases is highly conserved throughout mammals [4]. This suggests the existence of distinct benefits and, potentially, important physiological functions.

A definitive, fully satisfactory understanding of the physiological function of PrPC has been lacking for a long time. Very recently, we identified a native function of PrPC in the peripheral nervous system and the underlying mechanism of that function [5]. However, PrPC is also highly expressed in the central nervous system (CNS) and its biological activity there is still far from being clear. This review will focus on the proposed roles of cellular prion protein in the central and peripheral nervous systems.

The prion protein undergoes post-translational proteolytic processing

The cellular prion protein is encoded by the Prnp gene. In mice, the entire protein-coding open-reading frame is encoded within the third exon of Prnp [6,7,8]. After translation and cotranslational extrusion into the lumen of the endoplasmic reticulum, PrPC adopts its physiological structure with a C-terminal globular domain and an N-terminal flexible tail [9] (Fig. 1). The N-terminal tail consists of two charged clusters (CC1 and CC2), the octarepeat region (OR) and a hydrophobic domain (HD). Additionally, two N-glycosylation sites are located in the globular domain upstream of the sialylated GPI-anchor at the C-terminus [10, 11].

Fig. 1

Structural organization of PrPC. Schematic representation of mature mouse PrPC, showing protein domains, sites of post-translational modification, and binding sites for divalent cations and protein interactors of functional relevance. CC1 charge cluster 1, OR octapeptide repeats, CC2 charge cluster 2, HD hydrophobic domain, FT flexible tail, GD globular domain. Structurally defined domains are depicted by pink (α-helix) and green (β-strand) boxes. GPI glycosylphosphatidylinositol anchor, CHO glycosylation site, S-S disulfide bridge. α, β, and γ cleavage sites are indicated. Copper binding sites (Cu 2+) within and outside the octapeptide region are reported as well as the sites involved in the interaction with Aβ oligomers and with the G-protein-coupled receptor Adgrg6

After being transported to the cell membrane, PrPC resides extracellularly in lipid rafts, where it is attached to the outer leaflet by a glycosyl phosphoinosityl (GPI) anchor [12]. It undergoes rapid constitutive endocytosis and subsequently either recycling or degradation [13, 14]. PrPC endocytosis can occur by both clathrin-dependent [15] and caveolin pathways [16].

As part of its post-translational metabolism, PrPC can undergo proteolytic cleavage events termed, in analogy to amyloid precursor protein processing, α-, β-, and possibly also γ-cleavage (Fig. 1). These cleavage events release the so-called N1 + C1, N2 + C2, and C3 fragments, respectively [17,18,19,20]. These events may be important for both physiology and pathology. Alpha cleavage prevents the C1 fragment from being converted into PrPSc [21], the rate of the beta cleavage is increased in the disease [19], and PrPC deletion mutants lacking the alpha-cleavage site show spontaneous neurodegeneration exhibiting pathological features distinct from those of prion diseases (reviewed in [22]).

The enzyme responsible for PrPC cleavage may not be unique, and several members of the ADAM (a_disintegrin and metalloproteinase) family have been implicated [23,24,25,26]. PrPC can bind divalent cations such as copper and zinc [27] by the octarepeat-containing flexible tail and it has been reported to interact with a plethora of different proteins. These interactions have been taken to reflect its putative role in several cellular processes, but they may also simply be a consequence of the unstructured, flexible conformation of the N-terminus of PrPC.

Genetic pitfalls of PrPC gene ablation

Soon after PrPSc was proposed to be the causative agent of prion diseases, Prnp knockout mice lacking PrPC were generated in order to answer the question whether the loss of physiological PrPC function would lead to neurodegeneration in prion diseases. The first Prnp null mouse strain, designated Prnp -/-, or Zurich I (ZrchI, Prnp ZH1/ZH1), was produced in a mixed C57BL/6 J × 129/Sv(ev) background [28] and a second line of PrPC-deficient mice, known as Npu or Edinburgh (Edbg), was produced with a pure 129/Ola genetic background [29]. In a first round of characterization, these mice were not found to show any clear abnormality except for their resistance to prion infection [30]. They developed and bred normally, and although they displayed subtle alterations in behavior [28], their otherwise apparent normality seemed to rule out a physiological function of PrPC that is essential for life. If there is one, it is highly redundant or it can be compensated for. PrPC-deficient mice from which the entire Prnp gene was removed [31,32,33,34] develop progressive cerebellar ataxia, which was originally attributed to the loss of PrPC but was later discovered to be due to the deletion of a splice acceptor site in exon 3 of Prnp [35]. This led to aberrant overexpression of the PrPC paralogue gene (Prnd) encoding Doppel (Dpl) [36, 37], causing selective neurodegeneration of cerebellar Purkinje cells. Notably, the reintroduction of Prnp in mice overexpressing Prnd in the brain rescued the phenotype, suggesting a functional link between the two proteins [38].

Later, using the Cre-loxP system, conditional PrPC knockout NFH-Cre/tg37 mice were generated to examine the effects of acute PrPC depletion on neuronal viability and function in the brain of 9-week-old adults. This approach was thought to avoid compensatory mechanisms active at the embryonal stage that would have masked PrPC loss of function phenotypes [39]. Again, depleting neuronal PrPC in adult mice did not result in neurodegeneration or histopathological changes, but it led to subtle electrophysiological abnormalities in the hippocampus (Table 1). A closer look at different neuronal and other cell functions in PrPC-ablated mice revealed a number of differences from wild-type mice that were attributed to the physiological function of PrPC. While some of these studies were consistent among different PrPC-deficient lines, others yielded contradictory results depending on methodologies and the mouse models that were used (Table 2).

Table 1 Lines of PrPC-ablated mice covered in this review
Table 2 Proposed physiological roles of cellular prion protein

A genetic confounder has been shown to underlie some of these inconsistencies [40, 41]. For many years, knockout alleles were usually created in embryonic stem cells from the Sv129 strain of mice, and the resulting mice were backcrossed to C57BL/6 mice [42]. This practice typically leads to variable, poorly controlled Mendelian segregation of polymorphic alleles whose distribution depends on their genetic linkage to the knockout allele. All Prnp knockout mouse lines have been generated in this way with the exception of the “Edinburgh” mouse, which was maintained in a pure 129 background [42]. Even after more than 12 generations of backcrossing, a small part of the chromosome around the Prnp locus still stems from the 129 strain, raising the question whether any observed phenotypes were actually due to polymorphisms in genes flanking Prnp. Indeed, we found that SIRPα, a polymorphic Prnp-flanking gene, is actually responsible for an alleged Prnp -/- phenotype: the inhibition of macrophage phagocytosis of apoptotic cells that was observed in PrPC-deficient mice with mixed genetic background but not in co-isogenic Prnp -/- mice [40]. Recently, a new PrPC-deficient mouse strain, Prnp ZH3/ZH3, was produced in our lab using TALEN-mediated genome editing in fertilized mouse oocytes and maintained in a pure C57BL/6 J genetic background [42]. These strictly co-isogenic C57BL/6 J-Prnp ZH3/ZH3 mice differ from wild-type mice only by eight deleted nucleotides in the Prnp reading frame. In an effort to improve the quality of studies on the function of the cellular prion protein, we are distributing Prnp ZH3/ZH3 mice without requesting any kind of Material Transfer Agreement, hence enabling better-controlled future studies. In view of the broad availability of Prnp ZH3/ZH3 mice, we contend that the use of mixed-background PrPC-deficient mice is obsolete and liable to artifacts.

Do further mammal species teach us more about the function of PrPC? The gene encoding PrPC has been ablated experimentally in cattle [43] and goats [44], and a naturally occurring Prnp knockout goat has been reported [45]. While no pathological phenotypes were reported in any of these animals, it may be rewarding to perform specific investigations of these animals, e.g., concerning the integrity of the peripheral nervous system in advanced age.

A large set of human genomic data was analyzed to quantify the penetrance of variants of the human PrPC gene (PRNP) in prion disease [46]. Surprisingly, heterozygous loss-of-function variants were identified in three individuals. These individuals in their 50s and 70s are probably healthy, and no evidence of any neurological defect or peripheral neuropathy was documented. This result suggests that heterozygous loss of PRNP in humans may not be haploinsufficient. It remains to be assessed, however, whether homozygous deletion and therefore complete loss of PrPC may create a disease in humans.

Evidence for a role of synaptic PrPC in memory and sleep

PrPC is strongly expressed in both neurons and glial cells of the CNS [1]. In neurons, PrPC is preferentially localized in the pre- and postsynaptic compartments of nerve terminals. Immunocytochemical studies by light and electron microscopy in primate and rodent brains [47, 48], as well as examination of an EGFP-tagged PrPC in transgenic mice, showed that PrPC is enriched along axons and in pre-synaptic terminals [49, 50] and that it undergoes anterograde and retrograde axonal transport [51, 52]. PrPC is also present in postsynaptic structures [53, 54]. It has recently been shown that sialic acid within the GPI-anchor is important for targeting PrPC to synapses [55]. This expression pattern implies that PrPC might be involved in preserving normal synaptic structure and function by regulating synaptic transmission and plasticity (Fig. 3). Supporting this notion, synaptic dysfunction and synaptic loss are a prominent and early event in prion diseases [56, 57].

Early reports showed that PrPC-deficient mice (both ZH1 and Edbg) display reduced long-term potentiation (LTP) in hippocampal Schaffer collaterals and weakened inhibitory GABAergic synaptic transmission [58, 59]. These defects have been claimed to be rescued by a human PRNP transgene [60]. However, none of these results were reproduced in PrPC-deficient mice of three different genetic backgrounds (Table 2). These discrepancies have remained essentially unexplained for the past 20 years [61]. Later studies reported a PrPC dosage-dependent facilitation of synaptic transmission, with PrPC-over-expressing mice exhibiting supra-physiological synaptic transmission [62]. This effect seemed to result from a more efficient recruitment of pre-synaptic fibers that, in turn, may depend on PrPC expression levels.

LTP is one of the neurophysiological correlates of synaptic plasticity, the ability of synapses to change their strength in response to previous activity. Because synaptic plasticity (LTP) in the hippocampus underlies learning and memory formation [63], any LTP deficits may result in cognitive defects. Initial reports did not show any reduction in memory performance of Prnp ZH1/ZH1 mice in the Morris Water Maze test [28]. However, a later study found deficiencies in spatial learning and memory in PrPC-deficient mouse lines on various backgrounds [64]. These deficits were explained by reduced LTP in the dentate gyrus in PrPC-deficient mice in vivo, and were rescued by neuronal expression of PrPC. Prnp ZH1/ZH1 mice were reported to have impaired memory performance only when aged (9 months). Several molecular mechanisms for this defect have been proposed, but none were verified at the mechanistic level [65,66,67]. These results stand in contrast to another study carried out in Prnp ZH1/ZH1 mice that did not reveal any memory impairment up to an age of 2 years [68]. Thus, a role for PrPc in memory is still contentious.

A role of PrPC in sleep homeostasis and sleep continuity has also been proposed and loss of such a function for PrPC would be of clinical relevance. Indeed, it would explain the disruption of the sleep pattern that occurs as a prominent symptom in some forms of prion diseases like sporadic and familial fatal insomnia [69, 70]. Both Prnp ZH1/ZH1 and co-isogenic PrnpEdbg/Edbg mice were reported to display altered circadian rhythms, increased sleep fragmentation, and increased slow wave activity (SWA) following sleep deprivation [71]. The latter phenotype was rescued by reintroduction of PrPC expression [72]. It was suggested that the difference in SWA between wild-type and Prnp null mice reflected a function of PrPC in neurotransmission or a protective role on synapses [73]. Another study confirmed sleep disturbance in Prnp knockout mice. However, using a prolonged sleep deprivation protocol, the defect was found to be associated with reduced slow-wave activity and to altered hormonal reactivity to prolonged stress [74]. Interestingly, deterioration of slow-wave activity was found to contribute to sleep deficits in Alzheimer’s disease (AD) and was reversed by enhancing GABAAergic inhibition [75].

The molecular bases of sleep regulation are not completely understood. Tantalizingly, recent work indicates that calcium-dependent hyperpolarization is critical to sleep duration, and that sleep deterioration is associated with impairment of calcium-dependent potassium channels, voltage-gated calcium channels (VGCC), and N-methyl-D-aspartate (NMDA) glutamate receptors [76]. Since both hyperpolarization linked to calcium dyshomeostasis and NMDA receptor-related hyperexcitability were documented in Prnp ablated mice (discussed in the next section), loss of PrPC-dependent control of these ion channels may underlie the sleep disruption in PrPC-deficient mice and perhaps also in prion diseases.

Possible functions for PrPC are suggested by interaction partners

Albeit controversial, the participation of PrPC in neurobiological processes, and particularly in sleep regulation and memory, raises the question whether the cellular prion protein modulates synaptic mechanisms and neuronal excitability at a molecular level. Insights into possible mechanisms may be provided by the documented interaction of PrPC with several ion channels and metabotropic glutamate receptors (Fig. 2). However, caution is needed while screening the crowded PrPC interactome: only interactions with molecular partners displaying a functional correlate to PrPC binding should be considered of potential biological relevance.

Fig. 2

PrPC exerts its functions via distinct mechanisms. The cellular prion protein may utilize several mechanisms to modulate cellular functions. As schematically depicted in a, PrPC may directly alter the function of its target protein by mediating posttranslational modifications, for example, by promoting the S-nitrosylation of the NMDA receptor. Alternatively, PrPC modulates auxiliary proteins of ion channels, thereby regulating the biophysical properties of the channel (b) or its trafficking (c). Another function of PrPC arises from its ability to bind divalent cations such as zinc (Zn2+) or copper (Cu2+). It was claimed that PrPC may buffer these cations within the synaptic cleft and may facilitate their uptake (d) via AMPA receptors. Some better-defined actions of PrPC include its binding to misfolded oligomeric protein species and signaling in complex with other membrane receptors (e). Additionally, PrPC can signal in trans by its N-terminal cleavage products, which may bind to other receptors, prominently including the G-protein-coupled receptor Adgrg6 (f)

PrPC interacts with Dipeptidyl peptidase-like 6 (DPP6), an auxiliary subunit of the voltage-gated potassium channel 4.2 (Kv4.2), which leads to increased and prolonged currents through this channel, thereby reducing cellular excitability [77]. Also, PrPC and a mutant PrPC version that is linked to a genetic prion disease have been shown to co-immunoprecipitate with the auxiliary subunit α2δ-1 of VGCCs in transgenic mice [78]. Mutant PrPC affected α2δ-1 trafficking and function at the synapses. The molecular role of PrPC in VGCC function under physiological conditions remains unclear (Fig. 3). However, deficits in VGCC currents and calcium homeostasis were reported in Prnp ZH1/ZH1 neurons [79, 80] and were proposed to underlie the reduced slow after hyperpolarization (sAHP) seen in PrPC-deficient mice. The sAHP is a property of many neurons that is evoked by repetitive action potentials and controls subsequent action potential firing. The intermediate-conductance, calcium-activated potassium channel (IkCa) has been claimed to control this neurophysiological parameter [81].

Fig. 3

Schematic overview of possible physiological functions of PrPC and their effect in the central nervous system. PrPC regulates ion channels and neurotransmitter receptors at the pre- and postsynaptic levels. a PrPC might modulate VGCC trafficking at the presynapse via interaction with the α2δ-1 VGCC subunit. b Postsynaptically, PrPC dampens NMDA receptor-mediated currents by modulating various receptor subunits of this channel. It was speculated that control of NMDA receptor function might be related to certain reported phenotypes of PrPC-ablated mice. c PrPC may also control the glutamatergic system by modulating the subunit composition of kainate receptors. This possibly relates to increased susceptibility of PrPC-ablated mice to kainate-induced seizures. d PrPC associates with, and promotes cell surface localization of, AMPA receptor subunits. This facilitates zinc uptake at the synaptic cleft via AMPA receptors. On astrocytes, a PrPC–AMPA complex may be involved in the uptake of lactate. e PrPC binds to toxic oligomeric protein species. PrPC binds to Aβ oligomers and, in complex with metabotropic glutamate receptor 5 (mGluR5), was proposed to trigger intracellular signaling related to Alzheimer's disease pathology. f PrPC controls calcium influx via interaction with different ion channels. Additionally, PrPC was claimed to regulate calcium storage via the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA). g PrPC positively modulates potassium currents as exemplified by association with DPP6, an auxiliary subunit of the Kv 4.2 potassium channel. Control of calcium and potassium channels might be related to the alleged function of PrPC in neuronal excitability. ER endoplasmic reticulum

Not only could the sAHP defect be reproduced by independent research groups in Prnp ZH1/ZH1 mice [80, 82, 83], it has also been shown in an adult-onset model of PrPC depletion, indicating that this is not a developmental phenotype [39]. At the cellular level, reduced sAHP is expected to result in increased neuronal firing. Increased neuronal excitability in the PrPC-deficient hippocampus has also been reported in the context of higher vulnerability of PrPC-deficient mice to kainate-induced seizures (Fig. 3). This was related to the interaction of PrPC with the kainate receptor subunit GluR6/7 [84]. Additionally, in the absence of PrPC, GluR6/7-containing KA receptors were upregulated and the neurotoxic signaling was enhanced [84,85,86]. This suggests a neuroprotective role of PrPC against excitotoxic insults.

However, whether this represents a bona fide PrPC phenotype remains controversial. Prnp -/- mice on a different genetic background displayed a reduced susceptibility to kainate-induced seizures in the absence of PrPC. As this phenotype could not be rescued by reintroduction of an exogenous Prnp gene, it is suspected that polymorphisms in some unidentified Prnp-flanking genes may underlie the discrepant phenotypes [41]. More recently, however, although the effect of the “Prnp-flanking gene” in the KA-mediated responses was confirmed in PrPC-deficient mice of a mixed background (B6129 and B6.129), enhanced sensitivity to epileptogenic drugs was found in the co-isogenic Prnp Edbg/Edbg mouse [87]. The molecular mechanism underlying this phenotype is unclear but the aa32–93 region of PrPC (spanning the octapeptide repeats) and its glycosylphosphoinositol anchor may be involved. Consistent with the higher neuronal excitability of PrPC-deficient mice, anatomical changes within the hippocampus indicated a reorganization of neuronal circuitry similar to the “epileptic neuronal network” seen in certain human epilepsies [88].

PrPC might also act as a modulator of glutamate receptors of the NMDA subtype. These are heterotetramers composed of two GluN1 subunits and two GluN2 subunits of different subtypes [89]. It was found that PrPC inhibited NMDA receptors and prevented potentially excitotoxic calcium influx through these channels by association with NMDA receptors containing the GluN2D subunit [90], as shown by co-immunoprecipitation and immunofluorescence imaging. Absence of PrPC led to upregulation of GluN2D-containing NMDA receptors and enhanced signaling due to prolonged kinetics of NMDA-mediated currents [90]. This was subsequently linked to increased depressive-like behavior and increased nociception in PrPC-deficient mice. Both phenotypes were rescued by pharmacological inhibition of NMDA receptors [91, 92]. Additionally, copper-dependent interaction of PrPC with the GluN1 subunit was documented, which was involved in nitrosylation of NMDA subunits GluN2A and GluN1. This represents a second mechanism by which the presence of PrPC reduces NMDA currents and signaling [93, 94].

The putative control of ionotropic glutamate receptors by PrPC may be even more complex, since PrPC also interacts with α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunits GluA1 and GluA2. This interaction may be relevant to the PrPC-mediated cellular uptake of zinc through AMPA receptors [95] and to the regulation of lactate transport in astrocytes [96]. Whether the binding of PrPC with AMPA receptor subunits also plays a role in AMPA receptor function remains to be elucidated.

PrPC interactions with metabotropic glutamate receptors and Aβ

Recently, PrPC has been shown to interact not only with ionotropic but also with metabotropic glutamate receptors of group I, mGluR1 and mGluR5 (Fig. 2). Metabotropic glutamate receptors are members of the G protein-coupled receptor (GPCR) superfamily of seven transmembrane-domain proteins that are activated by glutamate and transduce intracellular signals via G proteins. PrPC binds to and signals through mGluR5 in disease-related conditions [97].

Several studies found that Aβ oligomers, the neurotoxic protein species involved in AD, can bind to PrPC [98, 99] (Figs. 1 and 2) and activate the Fyn kinase through mGluR5 [97]. Aβ–PrPC–mGluR5 complexes are responsible for facilitation of long-term depression (LTD) in vivo [100] and dendritic spine loss in cultured neurons [97]. The Aβ–PrPC–mGlu5R complex might act upstream of the phosphorylation of the NMDA receptor subunit GluN2B. This event within the pathogenic cascade triggered by Aβ oligomers requires PrPC-dependent Fyn activation [54] and underlies the Aβ oligomer-induced disruption of LTP in AD.

Focusing on the role of PrPC, two main considerations can be drawn from these studies. First, PrPC appears to function as a cell surface receptor for synaptotoxic oligomers of the Aβ peptide and, as reported by Resenberger and colleagues [101], of other β-sheet-rich neurotoxic proteins. However, whereas the physical interaction of PrPC with Aβ oligomers was confirmed [99, 102], it is unclear whether PrPC is necessary for the synaptotoxic effect of Aβ oligomers [102,103,104,105]. Secondly, although the interplay between mGluR5 and PrPC may be relevant to AD pathology, it remains unclear whether the binding to PrPC affects physiological functions of group I metabotropic glutamate receptors. Intriguingly, a role for the PrPC–mGluR1 complex in neurite outgrowth has been reported [106].

Role of PrPC in development

During murine embryonic development, PrPC is expressed as early as a few days post-implantation, suggesting a possible role in development [107, 108]. Transcriptomic analysis of PrPC knockout embryos showed several differentially expressed genes (DEGs), while the number of DEGs in brains of adult PrPC-deficient mice is almost negligible [42, 109]. Interestingly, the number of DEGs is higher in brains where PrPC had been knocked out postnatally, suggesting that the function of PrPC may be compensated for by other proteins during development [110]. To date, only a few in vivo studies on the role of PrPC in CNS development are available. They suggest that PrPC-ablated mice exhibit reduced proliferation rates of neuronal progenitor cells in the embryonic, newborn, and adult CNS [111, 112]. Additionally, increased proliferation of oligodendrocyte precursor cells with a concomitant maturation delay of oligodendrocytes and astrocytes has been reported [111, 113]. These observations were supported by the results of several in vitro experiments [111, 113, 114]. However, as the genetic background can influence brain development and adult neurogenesis [115], these studies should be confirmed in coisogenic PrPC-ablated mice.

Additionally, in vitro studies suggest that PrPC is implicated in the regulation of neuritogenesis [116, 117] as well as axonal growth [48, 118, 119]. Also, there is some evidence that PrPC is involved in the development of the cerebellar circuitry, leading to delayed motor development of PrPC-deficient mice [120].

Possible neuroprotective roles of PrPC

PrPC may have a neuroprotective role in a mouse model of cerebral ischemia, as PrPC-deficient mice show larger lesions in acute cerebral ischemia. Furthermore, overexpression of PrPC can reduce the lesion size compared to wild-type mice [121,122,123,124]. Attenuation of NMDA signaling by PrPC has been proposed to be the basis of a neuroprotective role of PrPC against NMDA-mediated toxicity in ischemia [125]. Additionally, it was found that cleavage of PrPC into its N- and C-terminal fragments is enhanced under ischemic conditions and these cleavage products can themselves be neuroprotective [124]. In particular, the N-terminal cleavage fragment (N1) might be neuroprotective against staurosporine-induced Caspase-3 activation in a model of pressure-induced ischemia in the rat retina [126]. These results are supported by several in vitro studies, where expression of PrPC was protective against staurosporine or anisomycin-induced apoptosis [127, 128]. Conversely, loss of PrPC was beneficial against glutamate-induced excitotoxicity in vitro, an effect supposedly mediated by increased uptake of glutamate in PrPC-ablated astrocytes [129].

The protective function of the N1 fragment is also very intriguing in the context of the Aβ oligomer-related synaptotoxicity. This intrinsically disordered N-terminal portion of PrPC is involved in binding to β-sheet-rich peptides like Aβ oligomers [99, 101] and mediates the detrimental effects of Aβ oligomers on synaptic function as mentioned before. However, in its soluble form as secreted upon PrPC cleavage, N1 acted in a decoy receptor-like mode: it prevented Aβ peptide fibrillization and reduced the neurotoxicity of amyloid-β oligomers in vitro and in vivo [130]. Additionally, the rate of PrPC alpha-cleavage is increased in brain tissue from patients suffering from AD and it was proposed that alpha-cleavage represents an endogenous protective mechanism against amyloid-β toxicity in humans [131].

However, PrPC-deficient mice do not exhibit altered amyloid-β toxicity [102,103,104,105] and there was no protective effect of PrPC in mouse models of other neurodegenerative diseases, including Parkinson's and Huntington's disease, as well as a mouse model of tauopathy [124, 132].

Based on in vitro studies, by virtue of its ability to bind copper, PrPC has been proposed to participate in resistance to oxidative stress by preventing reactive oxygen species (ROS) generation via free copper-mediated redox reactions. Also, PrPC was at some point thought to regulate the function of superoxide dismutase (SOD) [133]. It was even proposed that PrPC could act as a SOD by itself [27, 134]. However, a function of PrPC in copper metabolism is still controversial and the influence of PrPC on either SOD level or the intrinsic dismutase activity of PrPC was shown by us and others to be artifactual [135, 136]. There might be, however, alternative ways in which PrPC protects against ROS toxicity. For instance, PrPC-dependent expression of antioxidant enzymes was suggested as an explanation for resistance to oxidative stress mediated by PrPC [137, 138] as well as a conjectured PrPC function in iron metabolism and control of redox-iron balance in cell lines [139, 140].

Role of PrPC in the peripheral nervous system

PrPC-deficient mice of five different PrPC-knockout strains, including the Prnp ZH3/ZH3 mice (coisogenic to BL/6 mice), develop a late-onset peripheral neuropathy, indicating that peripheral myelin maintenance is a bona fide physiological function of PrPC [42, 141, 142]. PrPC neuronal expression and amino-proximal cleavage (Fig. 2) are necessary for the promyelinating signal [141]. It was then discovered that the very N-terminal polycationic cluster of PrPC binds to the G-protein-coupled receptor Adgrg6 (Gpr126) on Schwann cells (Fig. 1), eliciting a promyelinating cAMP response in vitro and in vivo in mice and zebrafish (Fig. 4) [5]. This pointed to the N-terminal fragment of PrPC as a promyelinating factor that might serve as a possible treatment in other peripheral chronic demyelinating polyneuropathies.

Fig. 4

Axonal PrPC promotes myelin maintenance in trans via Adgrg6 on Schwann cells. Mice devoid of PrPC develop a chronic demyelinating neuropathy, which suggested a pro-myelinating function of PrPC. In the peripheral nervous system, the N1 fragment of axonal PrPC interacts with Adgrg6 expressed on Schwann cells. This binding elicits activation of Adgrg6, which signals via adenylyl cyclase, thereby leading to increased cellular levels of cAMP. This triggers a well-defined downstream signaling cascade promoting myelin maintenance

In the CNS, Gpr126 is expressed by the Bergmann glia of the developing cerebellum, but not on mature oligodendrocytes, which are responsible for myelination [143]. However, some PrPC deletion mutants lacking the cleavage site for the N-terminal fragment production also showed severe demyelination in both the spinal cord and cerebellar white matter in vivo [144, 145]. Thus, although in the CNS an eventual PrPC function in myelin homeostasis is dispensable, a contribution of aberrant PrPC function in demyelinating diseases in the brain is a conceivable scenario. Moreover, whether the N-terminal cleavage product of PrPC is also signaling via other G-protein-coupled receptors in distinct biological processes is likely, but remains to be elucidated.

PrPC function: the next chapters

All available data point to PrPC exerting its function in concert with additional membrane proteins. On one hand, PrPC can regulate the cellular transport and localization of its binding partners. On the other hand, PrPC can directly modulate the functionality of the binding partner—as seen for certain ion channels and ionotropic glutamate receptors. Also, PrPC can signal in trans via its N-terminal cleavage products. Finally, PrPC appears to scavenge amyloid aggregates of Aβ, and it will be interesting to see whether further pathological aggregates can also be recognized by PrPC. Given these findings, the question arises whether the cellular prion protein needs its misfolding-prone structure with a disordered flexible tail to fulfill its physiological function. The fact that the functional domains of PrPC are conserved from avians to mammals speaks in favor of this hypothesis [4, 146]. Even though the interpretation of many studies is hampered by the genetic impurity of the mouse models used, there is enough evidence that PrPC plays a role in several physiological functions in the central and peripheral nervous systems. Nevertheless, it appears implausible that PrPC is involved in such a large number of cellular functions, particularly in view of the small number of validated pathological phenotypes in PrPC-deficient mice. The emergence of new, rigorously controlled animal models will be of help for revisiting and critically assessing some of these phenotypes.


  1. 1.

    Bendheim PE, Brown HR, Rudelli RD, Scala LJ, Goller NL, Wen GY, et al. Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology. 1992;42:149.

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216:136–44.

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Prusiner SB. Prions. Proc Natl Acad Sci U S A. 1998;95:13363–83.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Wopfner F, Weidenhöfer G, Schneider R, von Brunn A, Gilch S, Schwarz TF, et al. Analysis of 27 mammalian and 9 avian PrPs reveals high conservation of flexible regions of the prion protein. J Mol Biol. 1999;289:1163–78.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Küffer A, Lakkaraju AKK, Mogha A, Petersen SC, Airich K, Doucerain C, et al. The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6. Nature. 2016;536:464–8.

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Chesebro B, Race R, Wehrly K, Nishio J, Bloom M, Lechner D, et al. Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature. 1985;315:331–3.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Oesch B, Westaway D, Wälchli M, McKinley MP, Kent SBH, Aebersold R, et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell. 1985;40:735–46.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Westaway D, Cooper C, Turner S, Da Costa M, Carlson GA, Prusiner SB. Structure and polymorphism of the mouse prion protein gene. Proc Natl Acad Sci U S A. 1994;91:6418–22.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  9. 9.

    Riek R, Hornemann S, Wider G, Glockshuber R, Wüthrich K. NMR characterization of the full-length recombinant murine prion protein, mPrP (23–231). FEBS Lett. 1997;413:282–8.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Stahl N, Borchelt DR, Hsiao K, Prusiner SB. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell. 1987;51:229–40.

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Stahl N, Baldwin M, Hecker R, Pan K-M, Burlingame A, Prusiner S. Glycosylinositol phospholipid anchors of the scrapie and cellular prion proteins contain sialic acid. Biochemistry (Mosc). 1992;31:5043–53.

    CAS  Article  Google Scholar 

  12. 12.

    Naslavsky N, Stein R, Yanai A, Friedlander G, Taraboulos A. Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform. J Biol Chem. 1997;272:6324–31.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Morris RJ, Parkyn CJ, Jen A. Traffic of prion protein between different compartments on the neuronal surface, and the propagation of prion disease. FEBS Lett. 2006;580:5565–71.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Parizek P. Similar turnover and shedding of the cellular prion protein in primary lymphoid and neuronal cells. J Biol Chem. 2001;276:44627–32.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Taylor DR. Assigning functions to distinct regions of the N-terminus of the prion protein that are involved in its copper-stimulated, clathrin-dependent endocytosis. J Cell Sci. 2005;118:5141–53.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Peters PJ, Mironov A, Peretz D, van Donselaar E, Leclerc E, Erpel S, et al. Trafficking of prion proteins through a caveolae-mediated endosomal pathway. J Cell Biol. 2003;162:703–17.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. 17.

    Harris DA, Huber MT, Van Dijken P, Shyng SL, Chait BT, Wang R. Processing of a cellular prion protein: identification of N-and C-terminal cleavage sites. Biochemistry (Mosc). 1993;32:1009–16.

    CAS  Article  Google Scholar 

  18. 18.

    Walmsley AR, Watt NT, Taylor DR, Perera WSS, Hooper NM. α-cleavage of the prion protein occurs in a late compartment of the secretory pathway and is independent of lipid rafts. Mol Cell Neurosci. 2009;40:242–8.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Chen SG, Teplow DB, Parchi P, Teller JK, Gambetti P, Autilio-Gambetti L. Truncated forms of the human prion protein in normal brain and in prion diseases. J Biol Chem. 1995;270:19173–80.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Lewis V, Johanssen VA, Crouch PJ, Klug GM, Hooper NM, Collins SJ. Prion protein “gamma-cleavage”: characterizing a novel endoproteolytic processing event. Cell Mol Life Sci. 2016;73:667–83.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Westergard L, Turnbaugh JA, Harris DA. A naturally occurring C-terminal fragment of the prion protein (PrP) delays disease and acts as a dominant-negative inhibitor of PrPSc formation. J Biol Chem. 2011;286:44234–42.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Yusa S, Oliveira-Martins JB, Sugita-Konishi Y, Kikuchi Y. Cellular prion protein: from physiology to pathology. Viruses. 2012;4:3109–31.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Taylor DR, Parkin ET, Cocklin SL, Ault JR, Ashcroft AE, Turner AJ, et al. Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein. J Biol Chem. 2009;284:22590–600.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Vincent B, Paitel E, Saftig P, Frobert Y, Hartmann D, De Strooper B, et al. The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J Biol Chem. 2001;276:37743–6.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Altmeppen HC, Prox J, Puig B, Kluth MA, Bernreuther C, Thurm D, et al. Lack of a-disintegrin-and-metalloproteinase ADAM10 leads to intracellular accumulation and loss of shedding of the cellular prion protein in vivo. Mol Neurodegener. 2011;6:36.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Altmeppen HC, Prox J, Krasemann S, Puig B, Kruszewski K, Dohler F, et al. The sheddase ADAM10 is a potent modulator of prion disease. Elife. 2015;4, e04260.

    PubMed Central  Article  CAS  Google Scholar 

  27. 27.

    Brown DR, Clive C, Haswell SJ. Antioxidant activity related to copper binding of native prion protein. J Neurochem. 2001;76:69–76.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Büeler HR, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature. 1992;356:577–82.

    PubMed  Article  Google Scholar 

  29. 29.

    Manson JC, Clarke AR, Hooper ML, Aitchison L, McConnell I, Hope J. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol Neurobiol. 1994;8:121–7.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Büeler H, Aguzzi A, Sailer A, Greiner R-A, Autenried P, Aguet M, et al. Mice devoid of PrP are resistant to scrapie. Cell. 1993;73:1339–47.

    PubMed  Article  Google Scholar 

  31. 31.

    Sakaguchi S, Katamine S, Nishida N, Moriuchi R, Shigematsu K, Sugimoto T, et al. Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted PrP gene. Nature. 1996;380:528–31.

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Katamine S, Nishida N, Sugimoto T, Noda T, Sakaguchi S, Shigematsu K, et al. Impaired motor coordination in mice lacking prion protein. Cell Mol Neurobiol. 1998;18:731–2.

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    Moore RC. Gene targeting studies at the mouse prion protein locus [PhD Thesis]. Edinburgh, Scotland: University of Edinburgh; 1997.

  34. 34.

    Rossi D, Cozzio A, Flechsig E, Klein MA, Rülicke T, Aguzzi A, et al. Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl level in brain. EMBO J. 2001;20:694.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  35. 35.

    Weissmann C, Aguzzi A. PrP’s double causes trouble. Science. 1999;286:914.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Moore RC, Lee IY, Silverman GL, Harrison PM, Strome R, Heinrich C, et al. Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel. J Mol Biol. 1999;292:797–817.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Lu K, Wang W, Xie Z, Wong B-S, Li R, Petersen RB, et al. Expression and Structural characterization of the recombinant human doppel protein. Biochemistry (Mosc). 2000;39:13575–83.

    CAS  Article  Google Scholar 

  38. 38.

    Moore RC, Mastrangelo P, Bouzamondo E, Heinrich C, Legname G, Prusiner SB, et al. Doppel-induced cerebellar degeneration in transgenic mice. Proc Natl Acad Sci U S A. 2001;98:15288–93.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Mallucci GR, Ratte S, Asante EA, Linehan J, Gowland I, Jefferys JGR, et al. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J. 2002;21:202–10.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Nuvolone M, Kana V, Hutter G, Sakata D, Mortin-Toth SM, Russo G, et al. SIRP polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells. J Exp Med. 2013;210:2539–52.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Striebel JF, Race B, Pathmajeyan M, Rangel A, Chesebro B. Lack of influence of prion protein gene expression on kainate-induced seizures in mice: studies using congenic, coisogenic and transgenic strains. Neuroscience. 2013;238:11–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Nuvolone M, Hermann M, Sorce S, Russo G, Tiberi C, Schwarz P, et al. Strictly co-isogenic C57BL/6 J- Prnp −/− mice: A rigorous resource for prion science. J Exp Med. 2016;213:313–27.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  43. 43.

    Richt JA, Kasinathan P, Hamir AN, Castilla J, Sathiyaseelan T, Vargas F, et al. Production of cattle lacking prion protein. Nat Biotechnol. 2007;25:132–8.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Yu G. Functional disruption of the prion protein gene in cloned goats. J Gen Virol. 2006;87:1019–27.

    CAS  PubMed  Article  Google Scholar 

  45. 45.

    Benestad SL, Austbø L, Tranulis MA, Espenes A, Olsaker I. Healthy goats naturally devoid of prion protein. Vet Res. 2012;43:87.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Minikel EV, Vallabh SM, Lek M, Estrada K, Samocha KE, Sathirapongsasuti JF, et al. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016;8:322ra9.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  47. 47.

    Salès N, Rodolfo K, Hässig R, Faucheux B, Di Giamberardino L, Moya KL. Cellular prion protein localization in rodent and primate brain. Eur J Neurosci. 1998;10:2464–71.

    PubMed  Article  Google Scholar 

  48. 48.

    Salès N, Hässig R, Rodolfo K, Di Giamberardino L, Traiffort E, Ruat M, et al. Developmental expression of the cellular prion protein in elongating axons. Eur J Neurosci. 2002;15:1163–77.

    PubMed  Article  Google Scholar 

  49. 49.

    Herms J, Tings T, Gall S, Madlung A, Giese A, Siebert H, et al. Evidence of presynaptic location and function of the prion protein. J Neurosci. 1999;19:8866–75.

    CAS  PubMed  Google Scholar 

  50. 50.

    Mironov A, Latawiec D, Wille H, Bouzamondo-Bernstein E, Legname G, Williamson RA, et al. Cytosolic prion protein in neurons. J Neurosci. 2003;23:7183–93.

    CAS  PubMed  Google Scholar 

  51. 51.

    Borchelt DR, Koliatsos VE, Guarnieri M, Pardo CA, Sisodia SS, Price DL. Rapid anterograde axonal transport of the cellular prion glycoprotein in the peripheral and central nervous systems. J Biol Chem. 1994;269:14711–4.

    CAS  PubMed  Google Scholar 

  52. 52.

    Moya KL, Hässig R, Créminon C, Laffont I, Di Giamberardino L. Enhanced detection and retrograde axonal transport of PrPc in peripheral nerve: cellular prion protein in peripheral nerve. J Neurochem. 2003;88:155–60.

    Article  CAS  Google Scholar 

  53. 53.

    Haeberle AM, Ribaut-Barassin C, Bombarde G, Mariani J, Hunsmann G, Grassi J, et al. Synaptic prion protein immuno-reactivity in the rodent cerebellum. Microsc Res Tech. 2000;50:66–75.

    CAS  PubMed  Article  Google Scholar 

  54. 54.

    Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, et al. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci. 2012;15:1227–35.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Bate C, Nolan W, McHale-Owen H, Williams A. Sialic acid within the glycosylphosphatidylinositol anchor targets the cellular prion protein to synapses. J Biol Chem. 2016;291:17093–101.

    CAS  PubMed  Article  Google Scholar 

  56. 56.

    Jeffrey M, Halliday WG, Bell J, Johnston AR, MacLeod NK, Ingham C, et al. Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus. Neuropathol Appl Neurobiol. 2008;26:41–54.

    Article  Google Scholar 

  57. 57.

    Šišková Z, Reynolds RA, O’Connor V, Perry VH. Brain region specific pre-synaptic and post-synaptic degeneration are early components of neuropathology in prion disease. PLoS One. 2013;8:e55004. Mallucci GR, editor.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  58. 58.

    Collinge J, Whittington MA, Sidle KCL, Smith CJ, Palmer MS, Clarke AR, et al. Prion protein is necessary for normal synaptic function. Nature. 1994;370:295–7.

    CAS  PubMed  Article  Google Scholar 

  59. 59.

    Manson J, Hope J, Clarke AR, Johnston A, Black C, MacLeod N. PrP Gene dosage and long term potentiation. Neurodegeneration. 1995;4:113–4.

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Whittington MA, Sidle KCL, Gowland I, Meads J, Hill AF, Palmer MS, et al. Rescue of neurophysiological phenotype seen in PrP null mice by transgene encoding human prion protein. Nat Genet. 1995;9:197–201.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Lledo PM, Tremblay P, DeArmond SJ, Prusiner SB, Nicoll RA. Mice deficient for prion protein exhibit normal neuronal excitability and synaptic transmission in the hippocampus. Proc Natl Acad Sci U S A. 1996;93:2403–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  62. 62.

    Carleton A, Tremblay P, Vincent JD, Lledo PM. Dose-dependent, prion protein (PrP)-mediated facilitation of excitatory synaptic transmission in the mouse hippocampus. Pflüg Arch Eur J Physiol. 2001;442:223–9.

    CAS  Article  Google Scholar 

  63. 63.

    Bliss TVP, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31–9.

    CAS  PubMed  Article  Google Scholar 

  64. 64.

    Criado JR, Sánchez-Alavez M, Conti B, Giacchino JL, Wills DN, Henriksen SJ, et al. Mice devoid of prion protein have cognitive deficits that are rescued by reconstitution of PrP in neurons. Neurobiol Dis. 2005;19:255–65.

    CAS  PubMed  Article  Google Scholar 

  65. 65.

    Coitinho AS, Roesler R, Martins VR, Brentani RR, Izquierdo I. Cellular prion protein ablation impairs behavior as a function of age. NeuroReport. 2003;14:1375–9.

    PubMed  Article  Google Scholar 

  66. 66.

    Coitinho AS, Freitas ARO, Lopes MH, Hajj GNM, Roesler R, Walz R, et al. The interaction between prion protein and laminin modulates memory consolidation. Eur J Neurosci. 2006;24:3255–64.

    PubMed  Article  Google Scholar 

  67. 67.

    Coitinho AS, Lopes MH, Hajj GNM, Rossato JI, Freitas AR, Castro CC, et al. Short-term memory formation and long-term memory consolidation are enhanced by cellular prion association to stress-inducible protein 1. Neurobiol Dis. 2007;26:282–90.

    CAS  PubMed  Article  Google Scholar 

  68. 68.

    Lipp H-P, Stagliar-Bozicevic M, Fischer M, Wolfer DP. A 2-year longitudinal study of swimming navigation in mice devoid of the prion protein: no evidence for neurological anomalies or spatial learning impairments. Behav Brain Res. 1998;95:47–54.

    CAS  PubMed  Article  Google Scholar 

  69. 69.

    Lugaresi E, Medori R, Montagna P, Baruzzi A, Cortelli P, Lugaresi A, et al. Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. N Engl J Med. 1986;315:997–1003.

    CAS  PubMed  Article  Google Scholar 

  70. 70.

    Mastrianni JA, Nixon R, Layzer R, Telling GC, Han D, DeArmond SJ, et al. Prion protein conformation in a patient with sporadic fatal insomnia. N Engl J Med. 1999;340:1630–8.

    CAS  PubMed  Article  Google Scholar 

  71. 71.

    Tobler I, Gaus SE, Deboer T, Achermann P, Fischer M, Rulicke T, et al. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature. 1996;380:639–42.

    CAS  PubMed  Article  Google Scholar 

  72. 72.

    Huber R, Deboer T, Tobler I. Prion protein: a role in sleep regulation? J Sleep Res. 1999;8:30–6.

    PubMed  Article  Google Scholar 

  73. 73.

    Huber R, Deboer T, Tobler I. Sleep deprivation in prion protein deficient mice and control mice: genotype dependent regional rebound. Neuroreport. 2002;13:1–4.

    PubMed  Article  Google Scholar 

  74. 74.

    Sánchez-Alavez M, Conti B, Moroncini G, Criado JR. Contributions of neuronal prion protein on sleep recovery and stress response following sleep deprivation. Brain Res. 2007;1158:71–80.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  75. 75.

    Busche MA, Kekuš M, Adelsberger H, Noda T, Förstl H, Nelken I, et al. Rescue of long-range circuit dysfunction in Alzheimer’s disease models. Nat Neurosci. 2015;18:1623–30.

    CAS  PubMed  Article  Google Scholar 

  76. 76.

    Tatsuki F, Sunagawa GA, Shi S, Susaki EA, Yukinaga H, Perrin D, et al. Involvement of Ca2 + -dependent hyperpolarization in sleep duration in mammals. Neuron. 2016;90:70–85.

    CAS  PubMed  Article  Google Scholar 

  77. 77.

    Mercer RCC, Ma L, Watts JC, Strome R, Wohlgemuth S, Yang J, et al. The Prion protein modulates A-type K+ currents mediated by Kv4.2 complexes through dipeptidyl aminopeptidase-like protein 6. J Biol Chem. 2013;288:37241–55.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  78. 78.

    Senatore A, Colleoni S, Verderio C, Restelli E, Morini R, Condliffe SB, et al. Mutant PrP suppresses glutamatergic neurotransmission in cerebellar granule neurons by impairing membrane delivery of VGCC α2δ-1 subunit. Neuron. 2012;74:300–13.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  79. 79.

    Herms JW, Korte S, Gall S, Schneider I, Dunker S, Kretzschmar HA. Altered intracellular calcium homeostasis in cerebellar granule cells of prion protein-deficient mice. J Neurochem. 2000;75:1487–92.

    CAS  PubMed  Article  Google Scholar 

  80. 80.

    Fuhrmann M, Bittner T, Mitteregger G, Haider N, Moosmang S, Kretzschmar H, et al. Loss of the cellular prion protein affects the Ca2+ homeostasis in hippocampal CA1 neurons. J Neurochem. 2006;98:1876–85.

    CAS  PubMed  Article  Google Scholar 

  81. 81.

    King B, Rizwan AP, Asmara H, Heath NC, Engbers JDT, Dykstra S, et al. IKCa channels are a critical determinant of the slow AHP in CA1 pyramidal neurons. Cell Rep. 2015;11:175–82.

    CAS  PubMed  Article  Google Scholar 

  82. 82.

    Colling SB, Collinge J, Jefferys JGR. Hippocampal slices from prion protein null mice: disrupted Ca2+-activated K+ currents. Neurosci Lett. 1996;209:49–52.

    CAS  PubMed  Article  Google Scholar 

  83. 83.

    Powell AD, Toescu EC, Collinge J, Jefferys JGR. Alterations in Ca2 + -buffering in prion-null mice: association with reduced afterhyperpolarizations in CA1 hippocampal neurons. J Neurosci. 2008;28:3877–86.

    CAS  PubMed  Article  Google Scholar 

  84. 84.

    Carulla P, Bribián A, Rangel A, Gavín R, Ferrer I, Caelles C, et al. Neuroprotective role of PrPC against kainate-induced epileptic seizures and cell death depends on the modulation of JNK3 activation by GluR6/7–PSD-95 binding. Mol Biol Cell. 2011;22:3041–54.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  85. 85.

    Maglio LE, Perez MF, Martins VR, Brentani RR, Ramirez OA. Hippocampal synaptic plasticity in mice devoid of cellular prion protein. Mol Brain Res. 2004;131:58–64.

    CAS  PubMed  Article  Google Scholar 

  86. 86.

    Rangel A, Burgaya F, Gavín R, Soriano E, Aguzzi A, del Río JA. Enhanced susceptibility ofPrnp-deficient mice to kainate-induced seizures, neuronal apoptosis, and death: Role of AMPA/kainate receptors. J Neurosci Res. 2007;85:2741–55.

    CAS  PubMed  Article  Google Scholar 

  87. 87.

    Carulla P, Llorens F, Matamoros-Angles A, Aguilar-Calvo P, Espinosa JC, Gavín R, et al. Involvement of PrPC in kainate-induced excitotoxicity in several mouse strains. Sci Rep. 2015;5:11971.

    PubMed  PubMed Central  Article  Google Scholar 

  88. 88.

    Colling SB, Khana M, Collinge J, Jefferys JGR. Mossy fibre reorganization in the hippocampus of prion protein null mice. Brain Res. 1997;755:28–35.

    CAS  PubMed  Article  Google Scholar 

  89. 89.

    Mayer ML. Structural biology of glutamate receptor ion channel complexes. Curr Opin Struct Biol. 2016;41:119–27.

    CAS  PubMed  Article  Google Scholar 

  90. 90.

    Khosravani H, Zhang Y, Tsutsui S, Hameed S, Altier C, Hamid J, et al. Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. Sci Signal. 2008;181:551.

    CAS  Google Scholar 

  91. 91.

    Gadotti VM, Bonfield SP, Zamponi GW. Depressive-like behaviour of mice lacking cellular prion protein. Behav Brain Res. 2012;227:319–23.

    CAS  PubMed  Article  Google Scholar 

  92. 92.

    Gadotti VM, Zamponi GW. Cellular prion protein protects from inflammatory and neuropathic pain. Mol Pain. 2011;7:1.

    Article  CAS  Google Scholar 

  93. 93.

    You H, Tsutsui S, Hameed S, Kannanayakal TJ, Chen L, Xia P, et al. A neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A. 2012;109:1737–42.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  94. 94.

    Gasperini L, Meneghetti E, Pastore B, Benetti F, Legname G. Prion protein and copper cooperatively protect neurons by modulating NMDA receptor through S-nitrosylation. Antioxid Redox Signal. 2015;22:772–84.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  95. 95.

    Watt NT, Taylor DR, Kerrigan TL, Griffiths HH, Rushworth JV, Whitehouse IJ, et al. Prion protein facilitates uptake of zinc into neuronal cells. Nat Commun. 2012;3:1134.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  96. 96.

    Kleene R, Loers G, Langer J, Frobert Y, Buck F, Schachner M. Prion protein regulates glutamate-dependent lactate transport of astrocytes. J Neurosci. 2007;27:12331–40.

    CAS  PubMed  Article  Google Scholar 

  97. 97.

    Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, et al. Metabotropic glutamate receptor 5 is a coreceptor for alzheimer Aβ oligomer bound to cellular prion protein. Neuron. 2013;79:887–902.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  98. 98.

    Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature. 2009;457:1128–32.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  99. 99.

    Chen S, Yadav SP, Surewicz WK. Interaction between human prion protein and amyloid-β (Aβ) oligomers: role of N-terminal residues. J Biol Chem. 2010;285:26377–83.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  100. 100.

    Hu N-W, Nicoll AJ, Zhang D, Mably AJ, O’Malley T, Purro SA, et al. mGlu5 receptors and cellular prion protein mediate amyloid-β-facilitated synaptic long-term depression in vivo. Nat Commun. 2014;5:3374.

    PubMed  PubMed Central  Google Scholar 

  101. 101.

    Resenberger UK, Harmeier A, Woerner AC, Goodman JL, Muller V, Krishnan R, et al. The cellular prion protein mediates neurotoxic signalling of [beta]-sheet-rich conformers independent of prion replication. EMBO J. 2011;30:2057–70.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  102. 102.

    Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, et al. Synthetic amyloid- oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A. 2010;107:2295–300.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  103. 103.

    Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, et al. Prion protein and Aβ-related synaptic toxicity impairment: Cellular prion protein and amyloid-β. EMBO Mol Med. 2010;2:306–14.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  104. 104.

    Kessels HW, Nguyen LN, Nabavi S, Malinow R. The prion protein as a receptor for amyloid-[bgr]. Nature. 2010;466:E3–4.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  105. 105.

    Cisse M, Sanchez PE, Kim DH, Ho K, Yu G-Q, Mucke L. Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J Neurosci. 2011;31:10427–31.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  106. 106.

    Beraldo FH, Arantes CP, Santos TG, Machado CF, Roffe M, Hajj GN, et al. Metabotropic glutamate receptors transduce signals for neurite outgrowth after binding of the prion protein to laminin γ1 chain. FASEB J. 2011;25:265–79.

    CAS  PubMed  Article  Google Scholar 

  107. 107.

    Manson J, West JD, Thomson V, McBride P, Kaufman MH, Hope J. The prion protein gene: a role in mouse embryogenesis? Development. 1992;115:117–22.

    CAS  PubMed  Google Scholar 

  108. 108.

    Tremblay P, Bouzamondo-Bernstein E, Heinrich C, Prusiner SB, DeArmond SJ. Developmental expression of PrP in the post-implantation embryo. Brain Res. 2007;1139:60–7.

    CAS  PubMed  Article  Google Scholar 

  109. 109.

    Benvegnu S, Roncaglia P, Agostini F, Casalone C, Corona C, Gustincich S, et al. Developmental influence of the cellular prion protein on the gene expression profile in mouse hippocampus. Physiol Genomics. 2011;43:711–25.

    CAS  PubMed  Article  Google Scholar 

  110. 110.

    Chadi S, Young R, Le Guillou S, Tilly G, Bitton F, Martin-Magniette M-L, et al. Brain transcriptional stability upon prion protein-encoding gene invalidation in zygotic or adult mouse. BMC Genomics. 2010;11:1.

    Article  CAS  Google Scholar 

  111. 111.

    Bribián A, Fontana X, Llorens F, Gavín R, Reina M, García-Verdugo JM, et al. Role of the cellular prion protein in oligodendrocyte precursor cell proliferation and differentiation in the developing and adult mouse CNS. PLoS One. 2012;7, e33872.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  112. 112.

    Steele AD, Emsley JG, Ozdinler PH, Lindquist S, Macklis JD. Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. Proc Natl Acad Sci U S A. 2006;103:3416–21.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  113. 113.

    Arantes C, Nomizo R, Lopes MH, Hajj GNM, Lima FRS, Martins VR. Prion protein and its ligand stress inducible protein 1 regulate astrocyte development. Glia. 2009;57:1439–49.

    PubMed  Article  Google Scholar 

  114. 114.

    Prodromidou K, Papastefanaki F, Sklaviadis T, Matsas R. Functional cross-talk between the cellular prion protein and the neural cell adhesion molecule is critical for neuronal differentiation of neural stem/precursor cells: PrP and NCAM in NPC neuronal differentiation. Stem Cells. 2014;32:1674–87.

    CAS  PubMed  Article  Google Scholar 

  115. 115.

    Kempermann G, Gage FH. Genetic influence on phenotypic differentiation in adult hippocampal neurogenesis. Stem Cells Mamm Brain. 2002;134:1–12.

    CAS  Google Scholar 

  116. 116.

    Santuccione A, Sytnyk V, Leshchyns’ka I, Schachner M. Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59 fyn and to enhance neurite outgrowth. J Cell Biol. 2005;169:341–54.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  117. 117.

    Pantera B, Bini C, Cirri P, Paoli P, Camici G, Manao G, et al. PrP c activation induces neurite outgrowth and differentiation in PC12 cells: role for caveolin-1 in the signal transduction pathway. J Neurochem. 2009;110:194–207.

    CAS  PubMed  Article  Google Scholar 

  118. 118.

    Hajj GNM, Lopes MH, Mercadante AF, Veiga SS, da Silveira RB, Santos TG, et al. Cellular prion protein interaction with vitronectin supports axonal growth and is compensated by integrins. J Cell Sci. 2007;120:1915–26.

    CAS  PubMed  Article  Google Scholar 

  119. 119.

    Kanaani J, Prusiner SB, Diacovo J, Baekkeskov S, Legname G. Recombinant prion protein induces rapid polarization and development of synapses in embryonic rat hippocampal neurons in vitro: Prion protein enhances neuronal polarization. J Neurochem. 2005;95:1373–86.

    CAS  PubMed  Article  Google Scholar 

  120. 120.

    Prestori F, Rossi P, Bearzatto B, Lainé J, Necchi D, Diwakar S, et al. Altered neuron excitability and synaptic plasticity in the cerebellar granular layer of juvenile prion protein knock-out mice with impaired motor control. J Neurosci. 2008;28:7091–103.

    CAS  PubMed  Article  Google Scholar 

  121. 121.

    Shyu W-C. Overexpression of PrPC by adenovirus-mediated gene targeting reduces ischemic injury in a stroke rat model. J Neurosci. 2005;25:8967–77.

    CAS  PubMed  Article  Google Scholar 

  122. 122.

    Weise J, Sandau R, Schwarting S, Crome O, Wrede A, Schulz-Schaeffer W, et al. Deletion of cellular prion protein results in reduced Akt activation, enhanced postischemic caspase-3 activation, and exacerbation of ischemic brain injury. Stroke. 2006;37:1296–300.

    CAS  PubMed  Article  Google Scholar 

  123. 123.

    Doeppner TR, Kaltwasser B, Schlechter J, Jaschke J, Kilic E, Bähr M, et al. Cellular prion protein promotes post-ischemic neuronal survival, angioneurogenesis and enhances neural progenitor cell homing via proteasome inhibition. Cell Death Dis. 2015;6, e2024.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  124. 124.

    Mitteregger G, Vosko M, Krebs B, Xiang W, Kohlmannsperger V, Nölting S, et al. The role of the octarepeat region in neuroprotective function of the cellular prion protein. Brain Pathol. 2007;17:174–83.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  125. 125.

    Black SAG, Stys PK, Zamponi GW, Tsutsui S. Cellular prion protein and NMDA receptor modulation: protecting against excitotoxicity. Front Cell Dev Biol. 2014;2:45.

    PubMed  PubMed Central  Article  Google Scholar 

  126. 126.

    Guillot-Sestier MV, Sunyach C, Druon C, Scarzello S, Checler F. The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo. J Biol Chem. 2009;284:35973–86.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  127. 127.

    Chiarini LB, Freitas ARO, Zanata SM, Brentani RR, Martins VR, Linden R. Cellular prion protein transduces neuroprotective signals. EMBO J. 2002;21:3317.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  128. 128.

    Lopes MH. Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuroprotection by distinct signaling pathways. J Neurosci. 2005;25:11330–9.

    CAS  PubMed  Article  Google Scholar 

  129. 129.

    Pathmajeyan MS, Patel SA, Carroll JA, Seib T, Striebel JF, Bridges RJ, et al. Increased excitatory amino acid transport into murine prion protein knockout astrocytes cultured in vitro. Glia. 2011;59:1684–94.

    PubMed  PubMed Central  Article  Google Scholar 

  130. 130.

    Fluharty BR, Biasini E, Stravalaci M, Sclip A, Diomede L, Balducci C, et al. An N-terminal fragment of the prion protein binds to amyloid- oligomers and inhibits their neurotoxicity in vivo. J Biol Chem. 2013.

  131. 131.

    Béland M, Bédard M, Tremblay G, Lavigne P, Roucou X. Aβ induces its own prion protein N-terminal fragment (PrPN1)–mediated neutralization in amorphous aggregates. Neurobiol Aging. 2014;35:1537–48.

    PubMed  Article  CAS  Google Scholar 

  132. 132.

    Steele AD, Zhou Z, Jackson WS, Zhu C, Auluck P, Moskowitz MA, et al. Context dependent neuroprotective properties of prion protein (PrP). Prion. 2009;3:240–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  133. 133.

    Brown DR, Schulz-Schaeffer WJ, Schmidt B, Kretzschmar HA. Prion protein-deficient cells show altered response to oxidative stress due to decreased SOD-1 activity. Exp Neurol. 1997;146:104–12.

    CAS  PubMed  Article  Google Scholar 

  134. 134.

    Brown DR, Boon-Seng W, Hafiz F, Clive C, Haswell SJ, Jones IM. Normal prion protein has an activity like that of superoxide dismutase. Biochem J. 1999;344:1–5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  135. 135.

    Waggoner DJ, Drisaldi B, Bartnikas TB, Casareno RLB, Prohaska JR, Gitlin JD, et al. Brain copper content and cuproenzyme activity do not vary with prion protein expression level. J Biol Chem. 2000;275:7455–8.

    CAS  PubMed  Article  Google Scholar 

  136. 136.

    Hutter G, Heppner FL, Aguzzi A. No superoxide dismutase activity of cellular prion protein in vivo. Biol Chem. 2005;384:1279.

    Google Scholar 

  137. 137.

    Klamt F, Dal-Pizzol F, Conte da Frota Jr ML, Walz R, Andrades ME, da Silva EG, et al. Imbalance of antioxidant defense in mice lacking cellular prion protein. Free Radic Biol Med. 2001;30:1137–44.

    CAS  PubMed  Article  Google Scholar 

  138. 138.

    White AR, Collins SJ, Maher F, Jobling MF, Stewart LR, Thyer JM, et al. Prion protein-deficient neurons reveal lower glutathione reductase activity and increased susceptibility to hydrogen peroxide toxicity. Am J Pathol. 1999;155:1723–30.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  139. 139.

    Gasperini L, Meneghetti E, Legname G, Benetti F. In absence of the cellular prion protein, alterations in copper metabolism and copper-dependent oxidase activity affect iron distribution. Front Neurosci. 2016;10:437.

    PubMed  PubMed Central  Article  Google Scholar 

  140. 140.

    Singh A, Kong Q, Luo X, Petersen RB, Meyerson H, Singh N. Prion protein (PrP) knock-out mice show altered iron metabolism: a functional role for PrP in iron uptake and transport. PLoS One. 2009;4, e6115.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  141. 141.

    Bremer J, Baumann F, Tiberi C, Wessig C, Fischer H, Schwarz P, et al. Axonal prion protein is required for peripheral myelin maintenance. Nat Neurosci. 2010;13:310–8.

    CAS  PubMed  Article  Google Scholar 

  142. 142.

    Nishida N, Tremblay P, Sugimoto T, Shigematsu K, Shirabe S, Petromilli C, et al. A mouse prion protein transgene rescues mice deficient for the prion protein gene from purkinje cell degeneration and demyelination. Lab Invest. 1999;79:689–97.

    CAS  PubMed  Google Scholar 

  143. 143.

    Koirala S, Corfas G. Identification of novel glial genes by single-cell transcriptional profiling of bergmann glial cells from mouse cerebellum. PLoS One. 2010;5, e9198.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  144. 144.

    Radovanovic I. Truncated prion protein and Doppel are myelinotoxic in the absence of oligodendrocytic PrPC. J Neurosci. 2005;25:4879–88.

    CAS  PubMed  Article  Google Scholar 

  145. 145.

    Baumann F, Tolnay M, Brabeck C, Pahnke J, Kloz U, Niemann HH, et al. Lethal recessive myelin toxicity of prion protein lacking its central domain. EMBO J. 2007;26:538–47.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  146. 146.

    Rivera-Milla E, Oidtmann B, Panagiotidis CH, Baier M, Sklaviadis T, Hoffmann R, et al. Disparate evolution of prion protein domains and the distinct origin of Doppel- and prion-related loci revealed by fish-to-mammal comparisons. Faseb J. 2006;20:317–9.

    CAS  PubMed  Google Scholar 

  147. 147.

    Herms JW, Kretzschmar HA, Titz S, Keller BU. Patch-clamp analysis of synaptic transmission to cerebellar Purkinje cells of prion protein knockout mice. Eur J Neurosci. 1995;7:2508–12.

    CAS  PubMed  Article  Google Scholar 

  148. 148.

    Nishida N, Katamine S, Shigematsu K, Nakatani A, Sakamoto N, Hasegawa S, et al. Prion protein is necessary for latent learning and long-term memory retention. Cell Mol Neurobiol. 1997;17:537–45.

    CAS  PubMed  Article  Google Scholar 

Download references


AA is the recipient of support from an Advanced Grant of the European Research Council (Prion2020), a European Union Framework 7 Grant (NEURINOX), the Swiss National Research Foundation, Sinergia grant #147660, the Clinical Research Priority Programs “Small RNAs” and “Human Hemato-Lymphatic Diseases”, and the EU Joint Programme on Neurodegenerative Disease Research (JPND) CureALS and REfrAME. M-AW was supported by an MD/PhD fellowship from the Swiss National Foundation. AS is a recipient of a Forschungskredit of the University of Zurich, grant number [FK – 16 – 048].

Authors’ contributions

M-AW, AS, and AA wrote the manuscript. All authors have read the manuscript and agree with its content.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information



Corresponding author

Correspondence to Adriano Aguzzi.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wulf, MA., Senatore, A. & Aguzzi, A. The biological function of the cellular prion protein: an update. BMC Biol 15, 34 (2017).

Download citation


  • Prion Disease
  • Metabotropic Glutamate Receptor
  • Cellular Prion Protein
  • Prnp Gene
  • Flexible Tail